Fresenius SE Return on Tangible Equity 2016-2026 | FSNUY

Current and historical return on tangible equity values for Fresenius SE (FSNUY) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Fresenius SE Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2026-06-30 $1.78B $3.74B 47.58%
2026-03-31 $1.71B $3.28B 52.16%
2025-12-31 $1.43B $2.94B 48.70%
2025-09-30 $1.27B $2.83B 44.90%
2025-06-30 $1.23B $2.73B 44.92%
2025-03-31 $0.45B $2.73B 16.43%
2024-12-31 $0.51B $2.66B 19.17%
2024-09-30 $-0.40B $2.45B -16.39%
2024-06-30 $-1.20B $5.06B -23.77%
2024-03-31 $-0.71B $3.44B -20.73%
2023-12-31 $-0.64B $1.93B -33.37%
2023-09-30 $0.27B $0.43B 62.71%
2023-06-30 $1.03B $-3.74B -27.59%
2023-03-31 $1.35B $-3.49B -38.72%
2022-12-31 $1.45B $-3.39B -42.58%
2022-09-30 $1.77B $-3.47B -50.90%
2022-06-30 $1.93B $-3.70B -52.22%
2022-03-31 $2.09B $-4.22B -49.58%
2021-12-31 $2.15B $-4.61B -46.63%
2021-09-30 $2.07B $-4.81B -43.03%
2021-06-30 $2.08B $-5.09B -40.91%
2021-03-31 $1.97B $-5.05B -38.96%
2020-12-31 $1.95B $-5.34B -36.49%
2020-09-30 $2.03B $-5.52B -36.76%
2020-06-30 $2.02B $-5.52B -36.65%
2020-03-31 $2.10B $-5.84B -35.94%
2019-12-31 $2.11B $-5.89B -35.78%
2019-09-30 $2.12B $-8.45B -25.13%
2019-06-30 $2.12B $-10.99B -19.27%
2019-03-31 $2.37B $-13.56B -17.45%
2018-12-31 $2.39B $-16.44B -14.55%
2018-09-30 $2.41B $-14.38B -16.75%
2018-06-30 $2.39B $-12.55B -19.02%
2018-03-31 $2.10B $-10.37B -20.28%
2017-12-31 $2.05B $-7.94B -25.81%
2017-09-30 $1.93B $-7.12B -27.02%
2017-06-30 $1.90B $-6.10B -31.20%
2017-03-31 $1.85B $-5.45B -33.97%
2016-12-31 $1.76B $-4.73B -37.30%
2016-09-30 $1.68B $-5.04B -33.31%
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $29.581B $25.873B
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
Stock Name Country Market Cap PE Ratio
Quest Diagnostics (DGX) United States $27.271B 23.22
DaVita (DVA) United States $12.179B 14.91
Encompass Health (EHC) United States $12.036B 20.89
Elanco Animal Health (ELAN) United States $11.491B 21.70
Chemed (CHE) United States $6.620B 23.60
RadNet (RDNT) United States $6.069B 175.27
LifeStance Health (LFST) United States $4.991B 100.46
Option Care Health (OPCH) United States $3.523B 14.89
Aveanna Healthcare Holdings (AVAH) United States $3.123B 21.68
Addus HomeCare (ADUS) United States $2.164B 19.57
Astrana Health (ASTH) United States $2.138B 22.69
Pennant (PNTG) United States $1.396B 36.34
U.S Physical Therapy (USPH) United States $1.220B 32.19
Daxor (DXR) United States $0.065B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.024B 0.00
Psychemedics (PMD) United States $0.000B 0.00